• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Mereo BioPharma Group plc - American Depositary Shares (NQ:MREO)

    2.040 -0.090 (-4.23%)
    Streaming Delayed Price Updated: 1:38 PM EDT, Oct 22, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Mereo BioPharma Group plc - American Depositary Shares

    < Previous 1 2 Next >
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREO
    From Pomerantz LLP
    Via GlobeNewswire
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREO
    From Pomerantz LLP
    Via GlobeNewswire
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREO
    From Pomerantz LLP
    Via GlobeNewswire
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREO
    From Pomerantz LLP
    Via GlobeNewswire
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREO
    From Pomerantz LLP
    Via GlobeNewswire
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREO
    From Pomerantz LLP
    Via GlobeNewswire
    Mereo BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Highlights
    From Mereo BioPharma Group plc
    Via GlobeNewswire
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREO
    From Pomerantz LLP
    Via GlobeNewswire
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREO
    From Pomerantz LLP
    Via GlobeNewswire
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREO
    From Pomerantz LLP
    Via GlobeNewswire
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREO
    From Pomerantz LLP
    Via GlobeNewswire
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREO
    From Pomerantz LLP
    Via GlobeNewswire
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREO
    From Pomerantz LLP
    Via GlobeNewswire
    Ultragenyx and Mereo BioPharma Announce UX143 Phase 3 Orbit Study for Osteogenesis Imperfecta Progressing to Final Analysis
    Data from Orbit and Cosmic studies expected around the end of the year 
    From Ultragenyx Pharmaceutical Inc.
    Via GlobeNewswire
    Mereo BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate Highlights
    From Mereo BioPharma Group plc
    Via GlobeNewswire
    Mereo BioPharma Reports Full Year 2024 Financial Results and Provides Corporate Highlights
    From Mereo BioPharma Group plc
    Via GlobeNewswire
    Mereo BioPharma to Participate in Fireside Chat at the Leerink Partners Global Healthcare Conference
    From Mereo BioPharma Group plc
    Via GlobeNewswire
    Mereo BioPharma Provides Update on Lead Clinical Programs
    From Mereo BioPharma Group plc
    Via GlobeNewswire
    Mereo BioPharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference
    From Mereo BioPharma Group plc
    Via GlobeNewswire
    Mereo BioPharma to Participate in Fireside Chat at the Jefferies London Healthcare Conference
    From Mereo BioPharma Group plc
    Via GlobeNewswire
    Mereo BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update
    From Mereo BioPharma Group plc
    Via GlobeNewswire
    Mereo BioPharma to Participate in Fireside Chat at the 2024 Cantor Global Healthcare Conference
    From Mereo BioPharma Group plc
    Via GlobeNewswire
    Mereo BioPharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update
    From Mereo BioPharma Group plc
    Via GlobeNewswire
    Mereo BioPharma Announces Pricing of $50 Million Underwritten Registered Direct Offering of American Depository Shares, Priced At-the-Market
    From Mereo BioPharma Group plc
    Via GlobeNewswire
    Ultragenyx and Mereo BioPharma Announce New Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Sustained Reductions in Fracture Rates Following Treatment with Setrusumab (UX143) in Patients with Osteogenesis Imperfecta (OI)
    From Ultragenyx Pharmaceutical Inc.
    Via GlobeNewswire
    Mereo BioPharma to Participate in Fireside Chat at the Jefferies Global Healthcare Conference
    From Mereo BioPharma Group plc
    Via GlobeNewswire
    Mereo BioPharma Reports First Quarter 2024 Financial Results and Provides Corporate Update
    From Mereo BioPharma Group plc
    Via GlobeNewswire
    Mereo BioPharma to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
    From Mereo BioPharma Group plc
    Via GlobeNewswire
    Mereo BioPharma Reports Full Year 2023 Financial Results and Provides Corporate Update
    From Mereo BioPharma Group plc
    Via GlobeNewswire
    Mereo BioPharma to Participate in Fireside Chat at the Leerink Partners Global Biopharma Conference
    From Mereo BioPharma Group plc
    Via GlobeNewswire
    < Previous 1 2 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.